CIPRODEX - (0.3%; 0.1%; Suspension/Drops, Otic)

Generic Name	CIPROFLOXACIN; DEXAMETHASONE	**Innovator**	Novartis
Dosage	0.3%; 0.1%; Suspension/Drops, Otic	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	Less Than 5
Other ANDA developers	More Than 5	**Tentative Approvals**	None
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions of Acute Ottis Media and Acute Ottis Externa.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.